Thymoma
Drug research and approvals for thymoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 19, 2026, 31 studies of thymoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 31
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- AXIS MG Patient RegistryNCT07761026 · Not reported · Autoimmune Neurology Alliance · starts Mar 19, 2026
- Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic CarcinomaNCT07598955 · Phase 1 / Phase 2 · Beijing Biotech · starts Mar 2, 2026
- Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic CarcinomaNCT07324629 · Phase 2 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · starts Mar 13, 2026
- An International Study on Pediatric Patients With Rare Tumors.NCT07072143 · Not reported · Azienda Ospedaliera di Padova · starts Jan 25, 2025
- Prospective Data Collection Initiative on Thoracic MalignanciesNCT06996249 · Not reported · Dutch Society of Physicians for Pulmonology and Tuberculosis · starts Aug 15, 2025
- Neoadjuvant Radiotherapy for Locally Advanced Unresectable ThymomaNCT06924619 · Phase 2 · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts Oct 30, 2024
- Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors…NCT06885697 · Phase 1 · National Cancer Institute (NCI) · starts Jul 8, 2025
- Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic CarcinomaNCT06838910 · Phase 2 · The First Affiliated Hospital with Nanjing Medical University · starts Mar 31, 2025
- Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable ThymomaNCT06730308 · Phase 2 · Sun Yat-sen University · starts Nov 20, 2024
Phase 2 12 of 26
- CisplatinDNA inhibitor
- PaclitaxelTubulin inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- CarboplatinDNA inhibitor
- SunitinibMacrophage colony stimulating factor receptor inhibitor
- CyclophosphamideDNA inhibitor
- RamucirumabVascular endothelial growth factor receptor 2 inhibitor
- SelinexorExportin-1 inhibitor
- ErfonrilimabCytotoxic T-lymphocyte protein 4 inhibitor
- EpirubicinDNA inhibitor
- Sacituzumab govitecanTumor-associated calcium signal transducer 2 binding agent
- BevacizumabVascular endothelial growth factor A inhibitor
Phase 1 or earlier 4
- DoxorubicinDNA topoisomerase II alpha inhibitor
- BosutinibTyrosine-protein kinase ABL inhibitor
- ImatinibTyrosine-protein kinase ABL inhibitor
- Povidone-iodine
How its trials ended
113 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 23 whose ending is known, 22% met their primary endpoint, 9% missed it and 70% stopped early.
- Ongoing4237%
- Completed, result not reported3430%
- Status unknown1412%
- Stopped: other or unclear76%
- Met its primary endpoint54%
- Stopped: lack of efficacy54%
- Stopped: enrollment or feasibility33%
- Missed its primary endpoint22%
- Stopped: sponsor or business decision11%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Oct 25, 2018 | (1R,2R)-1,2-cyclohexane-diaminepyrophosphato-platinum(II)Treatment of thymoma and thymic carcinoma | Promontory Therapeutics, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA